Yang Z.,Shandong Agricultural University |
Jiang W.,Shandong Agricultural University |
Liu F.,Tumor Center |
Zhou Y.,Shandong Agricultural University |
And 2 more authors.
A novel electrochemical immunosensor was fabricated for the quantitative detection of 5-hydroxymethylcytosine (5-hmC) in genomic DNA based on anti-5-hmC antibody, biotin functionalized phos-tag and avidin functionalized alkaline phosphatase. It is demonstrated that the levels of 5-hmC are dramatically reduced in human breast cancer tissue compared with those in normal tissue. © The Royal Society of Chemistry 2015. Source
Xia L.-P.,Sun Yat Sen University |
Zhou F.-F.,Sun Yat Sen University |
Zhou F.-F.,Tumor Center |
Guo G.-F.,Sun Yat Sen University |
And 4 more authors.
Chinese Medical Journal
Backgroud It is not clear if there is a difference in prognosis between male breast cancer (MBC) and female breast cancer (FBC) patients. The aim of this study was to compare the prognosis of MBC and FBC patients in China and the prognosis of MBC and their corresponding postmenopausal FBC patients. Methods Thirty-five MBC patients who were treated at the Sun Yat-sen University Cancer Center between 1969 and 2004 were enrolled in the study. Seventy FBC patients who were matched with the MBC patients for TNM stage, year of diagnosis, and age at diagnosis were simultaneously enrolled in the study. A second group comprising 18 MBC patients and their corresponding 36 matched postmenopausal FBC patients were also enrolled. The whole group and the postmenopausal groups were compared for five- and ten-year survivals. Results All the factors that could potentially affect prognosis were comparable among the groups except more FBC than MBC patients underwent endocrine therapy and a modified radical mastectomy. The 5- and 10-year survivals in the whole group were 81.6% and 60.3% for men and 90.7% and 73.5% for women (P=0.02). The 5- and 10-year survival in the postmenopausal group was 82.5% and 100% for men and 66.0% and 85.9% for women (P=0.159). Conclusions Chinese FBC patients had a better prognosis than Chinese MBC patients. However, MBC patients and their corresponding postmenopausal FBC patients had a similar prognosis. Source
Pless M.,Medical Oncology |
Pless M.,Tumor Center |
Weinberg U.,Novocure Ltd.
Expert Opinion on Investigational Drugs
Introduction: Local control is fundamental, both for the curative as well as the palliative treatment of cancer. Tumor treating fields (TTFields) are low intensity (1 2 V/cm), intermediate frequency (100 200 kHz) alternating electric fields administered using insulated electrodes placed on the skin surrounding the region of a malignant tumor. TTFields were shown to destroy cells within the process of mitosis via apoptosis, thereby inhibiting tumor growth. TTFields have no effect on non-dividing cells. Areas covered: This article reviews in vitro and in vivo preclinical studies, demonstrating the activity of TTFields both as a monotherapy as well as in combination with several cytotoxic agents. Furthermore, it summarizes the clinical experience with TTFields, mainly in two indications: one in recurrent glioblastoma multiforme: in a large prospective randomized Phase III trial TTFields was compared with best standard care (including chemotherapy): TTFields significantly improved median overall survival (OS) compared with standard therapy (7.8 vs 6.1 months) for the patients treated per protocol. Importantly, quality of life was also better in the TTFields group. The second indication was a Phase II study in second-line non-small cell lung cancer, where TTFields was administered concomitantly with pemetrexed. This combination resulted in an excellent median OS of 13.8 months. Interestingly, the progression-free survival (PFS) within the area of the TTFields was 28, however, outside the TTFields the PFS was only 22 weeks. Expert opinion: The proof of concept of TTFields has been well demonstrated in the preclinical setting, and the clinical data seem promising in various tumor types. The side effects of TTFields were minimal and in general consisted of skin reaction to the electrodes. There are a number of ways in which TTFields could be further evaluated, for example, in combination with chemotherapy, as a maintenance treatment, or as a salvage therapy if radiotherapy or surgery is not possible. While more clinical data are clearly needed, TTFields is an emerging and promising novel treatment concept. © 2011 Informa UK, Ltd. Source
Wang F.,Sun Yat Sen University |
He W.,Sun Yat Sen University |
Qiu H.,Sun Yat Sen University |
Wang X.,Sun Yat Sen University |
And 7 more authors.
Clinical Breast Cancer
Background: The lymph node ratio (LNR) classification has shown superiority to pN staging (the number of positive lymph nodes) in breast cancers, but it has not been examined according to whether sufficient lymph nodes have been dissected. Methods: All Chinese patients with luminal A breast cancer with positive lymph nodes seen at Sun Yat-sen University Cancer Center between 1995 and 2009 were enrolled. Disease-free survival (DFS) and overall survival (OS) were the endpoints, and the patients were further classified into 2 groups according to whether ≤ 10 or > 10 lymph nodes were dissected. Results: For the whole group, the OS curves of the pN stages overlapped, whereas they were separated in the LNR survival curves. LNR was an independent prognostic factor for OS and DFS, whereas the pN stage was not. In the ≤ 10 lymph nodes dissected group, both OS and DFS curves were clearly separated in the pN staging but overlapped in the LNR classification. In the > 10 lymph nodes dissected group, LNR showed no overlap in the OS curves and was an independent prognostic factor of OS and DFS when compared with pN staging. Conclusion: In Chinese patients with luminal A breast cancer, LNR classification and the pN stage show different superiority as prognostic predictors according to whether > 10 or < 10 lymph nodes are dissected. © 2012 Elsevier Inc. Source
Zhang Q.,Shanghai University |
Tang J.,Shanghai University |
Lu X.,Shanghai University |
Cao X.,Tumor Center
Yi Qi Yi Biao Xue Bao/Chinese Journal of Scientific Instrument
Esophageal cancer is a huge threat to human health. In clinical diagnosis, doctors first get stained images of esophagus by using chromoendoscopy, and then visually observe the images and distinguish malignant lesions from benign lesions according to their clinical experience. It is time consuming, subjective, and associated with poor repeatability. In this paper, we present a method for computer-aided diagnosis of esophageal cancer based on chromoendoscopy images, which includes lesion detection, feature extraction, and classification. We first coarsely detect the regions of esophageal lesions with the skin color model, and then refine them with the region growing. Subsequently, we conduct the contourlet transform to the images and extract texture features from the detected lesions, and finally discriminate malignant esophageal lesions (i.e., cancer) from benign lesions (i.e., inflammatory lesions) by using the support vector machine (SVM). The experiments were carried out on 41 images from 26 patients, including 18 images of malignant lesions and 23 images of benign lesions. The results show that the classification accuracy of our method reached to 100%, indicating that the method of computer aided diagnosis can achieve accurate, objective, automated and fast diagnosis of esophageal cancer. Source